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Abstract
Background
Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in
low income countries, and incidence is rising rapidly in the developed world with the spread
of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infec-
tions and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like
Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in
determining both outcome of initial hepatitis infection and subsequent chronic liver disease
and tumour formation. HBV is highly prevalent in The Gambia and the commonest cause of
liver disease. The Gambia Liver Cancer Study was a matched case-control study conducted
between September 1997 and January 2001 where cases with liver disease were identified
in three tertiary referral hospitals and matched with out-patient controls with no clinical evi-
dence of liver disease.
Methods
We typed 15 KIR genes using the polymerase chain reaction with sequence specific primers
(PCR-SSP) in 279 adult Gambians, 136 with liver disease (HCC or Cirrhosis) and 143
matched controls. We investigated effects of KIR genotypes and haplotypes on HBV infec-
tion and associations with cirrhosis and HCC.
Results
Homozygosity for KIR group A gene-content haplotype was associated with HBsAg carriage
(OR 3.7, 95% CI 1.4–10.0) whilst telomeric A genotype (t-AA) was associated with reduced
risk of e antigenaemia (OR 0.2, 95% CI 0.0–0.6) and lower viral loads (mean log viral load
5.2 vs. 6.9, pc = 0.022). One novel telomeric B genotype (t-ABx2) containing KIR3DS1
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(which is rare in West Africa) was also linked to e antigenaemia (OR 8.8, 95% CI 1.3–60.5).
There were no associations with cirrhosis or HCC.
Conclusion
Certain KIR profiles may promote clearance of hepatitis B surface antigen whilst others pre-
dispose to e antigen carriage and high viral load. Larger studies are necessary to quantify
the effects of individual KIR genes, haplotypes and KIR/HLA combinations on long-term
viral carriage and risk of liver cancer. KIR status could potentially inform antiviral therapy
and identify those at increased risk of complications for enhanced surveillance.
Introduction
Hepatocellular carcinoma (HCC) is the commonest form of primary liver cancer and responsi-
ble for more than 800,000 deaths annually worldwide [1]. Developing countries carry the high-
est burden of disease with 70–85% of affected people living in Sub-Saharan Africa and Asia
[2]. In The Gambia, HCC is the commonest cancer in men [3].
Hepatitis B (HBV) and C (HCV) viruses are both major risk factors for liver cirrhosis and
HCC, together with exposure to aflatoxin in the diet which is common in West Africa [4,5,6].
Epidemiological studies show that when chronic viral hepatitis and dietary aflatoxin are both
present, the increase in risk of HCC is at least multiplicative [7,8]. HBV and HCV infections
are endemic in The Gambia, affecting over 90% of the population, with 15% to 20% chronically
infected with hepatitis B and 3% hepatitis C [4,9,10]. Detectable HBV viraemia confers a six
fold increase in risk of HCC, and higher levels (more than 10,000 viral copies/mL in serum)
are strongly associated with both HCC and cirrhosis (17- and 39-fold increased risk respec-
tively) [6].
NK cells play an important role in the innate host defence against viral infection and
tumour transformation and thus could be important in protecting against chronic hepatitis
infection and HCC. The actions of NK cells are mediated by direct cytotoxicity and secretion
of cytokines [11]. Cytotoxicity is controlled by tightly balanced opposing signals from inhibi-
tory and activatory killer-cell immunoglobulin-like receptors (KIR) present on the NK cell sur-
face. Cytokine secretion mediates interaction between NK cells and agents of the adaptive
immune system such as dendritic cells and T lymphocytes to modulate the host immune
response to pathogens and to abnormal cells [12].
The key function of KIR receptors is to survey the surfaces of other (target) cells to detect
the presence or absence of their cognate ligands which are human leukocyte antigen (HLA)
class I molecules. KIR and HLA interact in a complex fashion which may result in target cell
death [13,14]. Both activating and inhibitory pathways are likely to be governed by signals
transduced from interactions between specific KIR and HLA molecules. The control of the sys-
tem is such that reduction in MHC expression, as is often observed in tumours and virally
infected cells, increases the likelihood of killing by NK cells because of lack of KIR inhibition.
This ‘missing self’ model [15] proposed for NK cell detection of down regulation of HLA class
I makes KIR genotype important in a wide range of human diseases [16].
HLA class I down regulation by hepatitis B virus has been demonstrated in hepatoblastoma
cell lines [17] and decreased NK cell activity is also seen in patients with liver cancer [18]. In
addition, the degree of reduction in NK cell function may be associated with increased risk of
more invasive disease [19]. Several studies have investigated the role of KIR genes in a range of
KIR and hepatitis B in The Gambia
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virus related cancers [20,21,22,23] and suggested that presence of activating KIR confers
increased cancer risk–particularly for nasopharyngeal carcinoma [20] and cervical cancer [21].
Expression of activating KIR molecules is associated with susceptibility to chronic HCV
infection and cirrhosis and with inability to clear HCV following initial infection [22]. The
compound genotype KIR3DS1/Bw4-80I that favours NK cell activation is associated with
chronic HCV carriage in people with hepatocellular carcinoma [23] and inactivating KIR3DL1
is associated with spontaneous HCV clearance [24]. Whilst studies in hepatitis B are less com-
mon there is a suggestion that inactivating KIR may also protect against development of
chronic HBV infection [25].
In contrast however in other viral infections, activating KIR may be advantageous to the
host; for example KIR3DS1-HLA Bw4-80I confers protection from rapid progression to AIDS
following HIV-1 infection although the underlying mechanisms are likely to be different [26].
Some reports suggest that interaction between KIR molecules and their ligands on the target
cell surface is peptide specific [27,28] although this may not be universal [29].
KIR molecules in humans are encoded by a family of 16 genes located on chromosome 19
(Fig 1). This region of the human genome (approximately 150kb within the leukocyte receptor
complex [LRC]) is highly polymorphic and its organisation has yet to be mapped fully in
worldwide populations.
At the genomic level, KIR genes segregate into two clusters around a recombination hotspot
which are designated ‘centromeric’ and ‘telomeric’, each of which contains a variable number
of KIR genes. The composition and distribution of these clusters in populations distinguish
Fig 1. The genomic organisation of KIR genes on human chromosome 19. KIR genes are tightly
organised head-to-tail over approximately 150 kb within the Leukocyte Receptor Complex (LRC). Inhibitory
KIR genes are shown in green, activating genes in orange, pseudogenes in yellow, and the recombination
hotspot in black. KIR genes vary in size ranging from 10 kb to 16 kb and are separated from each other by
about 2 kb of intergenic space, except for the 14 kb recombination hotspot zone upstream of KIR2DL4 that
separates telomeric from centromeric KIRs.
https://doi.org/10.1371/journal.pone.0188307.g001
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individuals and ethnic groups. Studies on differences in KIR gene profiles (combinations of
the centromeric and telomeric elements of the KIR locus) between populations suggest a
differential contribution of each cluster to disease outcome [30,31]. Recent epidemiological
evidence has implicated telomeric B haplotypes containing activating genes with slow progres-
sion of chronic hepatitis C infection in American Aboriginals [32,33].
Whilst there is accumulating evidence for an important role for KIR in hepatitis C infection
[34], progression of disease [22], and development of hepatocellular carcinoma [23], there
have been few studies investigating KIR associations in HBV infection and subsequent liver
disease and cancer [35,36], although the underlying pathophysiological processes are likely to
be similar. In addition the full range of the KIR gene repertoire has not been fully mapped in
the genetically highly diverse African populations where hepatitis B is endemic and gives rise
to high rates of chronic hepatitis and hepatocellular carcinoma.
Thus in the present study, we characterised KIR profiles and studied the effects of centro-
meric and telomeric gene clusters on immunological markers of hepatitis B infection, viral
load, and liver disease in a well-characterised study group established by the International
Agency for Research on Cancer (IARC) Gambia Hepatitis Intervention Study (GHIS) program
under the Gambia Liver Cancer Case control study (GLCS) [4,6,37] in collaboration with the
UK Medical Research Council Laboratories in The Gambia and the Gambian Government.
Materials and methods
Study population
Participants were adult Gambians recruited into the GLCS between September 1997 and January
2001. DNA for the current study was available from 279 of 624 original participants (Table 1).
The GLCS was a case–control study conducted at three tertiary referral hospital sites in The
Gambia to determine the burden of hepatocellular carcinoma in the entire nation and to
examine aetiological factors [38]. Inclusion and exclusion criteria and methods have been
Table 1. Characteristics of study participants.
HCC
N (%)
Cirrhosis
N (%)
Liver disease
N (%)
Control
N (%)
OR
Total number 94 42 136 143
Gender
Male 76 (80.8) 30 (71.4) 106 (77.9) 94 (65.7) NA
Hepatitis B surface antigenaemia
Number tested 86 41 127 129 7.13
HBsAg+ 54 (62.8) 29 (70.7) 83 (65.3) 27 (20.9)
Hepatitis B "e" antigenaemia
Number tested 38 21 59 12 NA
HBeAg+ 8 (21.1) 8 (38.1) 16 (27.1) 0
HCV infection
Number tested 90 42 132 142 2
HCVAb 13 (14.4) 6 (14.3) 19 (14.4) 11 (7.8)
HBV viral load
Number tested 38 21 59 12 NA
MeanLog10HBV VL* 6.0 (4.5–7.3) 6.2 (4.5–7.6) 6.1 (4.5–7.6) 2.8 (2.4–3.1)
*: mean log HBV viral load (VL quantified as copies per mL) and inter-quartile range
N: number tested, NA: not applicable, liver disease: HCC+ Cirrhosis
https://doi.org/10.1371/journal.pone.0188307.t001
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described in detail elsewhere [4,6,37]. Briefly, patients with cancer and cirrhosis were identi-
fied from liver disease referral clinics at each of three sites (Royal Victoria Teaching Hospital
(RVTH), the Medical Research Council Clinic in Fajara and Bansang Hospital). Diagnosis of
primary liver cancer was confirmed by a) clinical evaluation b) serum alpha-fetoprotein levels
>100 ng/mL c) compatible ultrasound findings and/or histopathology diagnosis. A subset of
the cases had the diagnosis confirmed by liver biopsy (n = 54). Controls without clinical evi-
dence of liver disease were recruited from the outpatient clinics of the same hospitals, frequency
matched by sex and age (within 10 year groupings), and had normal alpha fetoprotein levels.
The Gambian population is ethnically highly diverse with five common culturally and lin-
guistically distinct groups. Participant evaluation included a structured interview that recorded
reported ethnicity, sociodemographic, lifestyle, and dietary factors. Blood and urine samples
were also collected together with extensive information from a standardized clinical examina-
tion. DNA was extracted from blood samples and archived at -80 oC.
KIR typing
Genomic DNA was typed for 14 functional KIR genes: 2DL1-5; 2DS1-5; 3DL1-3; 3DS1 and one
pseudogene (KIR2DP1) using the polymerase-chain reaction with sequence-specific primers
(PCR-SSP) [39]. Two pairs of KIR-specific primers were used to amplify segments of different
sizes from the same KIR gene if present. PCR products were stained with ethidium bromide in
2% agarose gel and visualised on a UV light box. Gel pictures were independently scored for
presence or absence of specific bands by two experienced scientists. Samples with discrepant
results were repeated and the gene considered present if one of the reaction pairs was consis-
tently positive upon repeat.
Mutations at the primer binding sites were confirmed by bi-directional sequencing using
primers flanking the region under investigation. Briefly, primers were designed using known
sequence from the KIR database [40]. The primers were then used to amplify a segment
including the binding sites where the SSP primer under investigation was designed to anneal.
The PCR product was then sequenced in both directions and traces analysed for mutations
using the Mutation Surveyor software (SoftGenetics LLC., State College, PA 16803, USA).
The use of two pairs of primers in the PCR-SSP technique to detect the same gene was to
limit false negative results due to PCR failure. The absence of specific bands on both reactions
was confirmed by repeating the typing and the gene was only considered absent when both
reactions remained negative following repeat. PCR efficiency was quality-controlled by adding
a pair of primers to every reaction which amplified a 796bp conserved fragment from the third
intron of the HLA-DRB1 gene.
Analysis of KIR gene motifs
KIR genes were assigned to centromeric and telomeric loci based on their chromosomal
positions relative to the recombination hotspot (RS) located between the framework genes
KIR3DP1 and KIR2DL4. KIR genes located upstream of RS are in the centromeric (Cen) gene
cluster whereas those located downstream are telomeric (Tel). The methods were derived from
techniques described by Cooley et al. [41] and Pyo et al. [42]. The gene-content of each of
these loci (Cen or Tel) per chromosomal strand is known as “motif” which carries a variable
number of activating and inhibitory KIR genes. Thus each sample has two Cen and two Tel
motifs making its centromeric genotype (e.g. c-AA or c-AB) and telomeric genotype (e.g.
t-AA or t-AB). The gene-content haplotype (also known as KIR profile) of each participant,
spanning the recombination hotspot, was constructed by combining each Cen locus to its cor-
responding Tel locus. The centromeric part of the locus may contains up to 10 KIR genes
KIR and hepatitis B in The Gambia
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including KIR3DL3, 2DS2, 2DL2, 2DL3, 2DL5, 2DS3, 2DS5, 2DP1, 2DL1 and 3DP1. The
remainder (KIR2DL4, 3DL1, 3DS1, 2DS1, 2DS4, and 3DL2) are located in the telomeric cluster.
KIR haplotypes are classified as group A or B depending on the presence of specific genes.
Thus group A haplotypes contain the inhibitory genes KIR3DL3, 2DL3, 2DL1, 2DL4, 3DL1,
and 3DL2, together with a single activating gene KIR2DS4. In contrast, group B haplotypes are
characterized by the presence of more than one activating KIR genes [43].
Data analysis
All statistical analyses were performed using STATA version 9.2 (Stata Corporation, Texas,
USA). Frequencies of the various genotypes and gene-content haplotypes were determined
and compared between groups. Observed KIR gene frequencies were determined by direct
counting and compared between HCC, Cirrhosis and Control groups using the Chi-square or
Fisher exact tests as appropriate. Viral load measurements were log transformed to normalise
the distribution and then compared between groups using t-tests. All p-values were corrected
for multiple comparisons using the Bonferroni technique.
Ethics statement
All participants were adults and gave written informed consent [4]. The GLCS was approved
by the Gambia Government/MRC Joint Ethics Committee (SCC 648).
Results
Patient characteristics
Approximately half of the participants had liver disease—either HCC or cirrhosis (Table 1). Those
with liver disease were more likely than controls to be hepatitis B surface antigen positive. A fifth
of control participants were long-term HBV carriers (HBsAg+). There were no significant differ-
ences in KIR gene frequencies or HBsAg carriage between ethnic groups. The prevalence of risk
factors and associations with disease status were similar to the original study [4,6].
KIR telomeric AA genotype is associated with absence of hepatitis B e
antigen and lower viral loads
We initially compared markers of long-term carriage of hepatitis B in participants with or
without individual KIR genes (Table 2). Carriers of KIR3DS1were more likely to be HBeAg
positive, although the gene was uncommon in this population. More detailed analysis of the
KIR motifs showed that homozygosity for group A KIR genes at the telomeric part of the KIR
locus (t-AA) was inversely related to hepatitis B e antigenaemia (Table 3). Carriers of this
genotype also had significantly lower HBV viral loads. We observed the opposite effect with
one of the novel telomeric genotypes which is heterozygous for A and B motifs at the telomeric
cluster (t-ABx2). The single difference between t-ABx2 and t-AA is the presence of the activat-
ing gene KIR3DS1 (Fig 2B). Participants with t-ABx2 genotypes were more likely than those
lacking this genotype to be HBeAg-positive (Table 3).
Heterozygosity for KIR content-haplotype is associated with reduced risk
of hepatitis B surface antigen carriage
45 distinct KIR profiles (S1 Table) were present in 279 participants from a recombination of 27
Cen and 8 Tel genotypes (S1 Fig). The most frequent profiles were c-AB2/t-AA and c-ABx1/t-
AA present in >15% of the study population (S1 Table).
KIR and hepatitis B in The Gambia
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Participants homozygous for group A haplotype (based on gene-content) were more likely
to be HBsAg-positive (Table 3). Conversely, heterozygosity at the KIR locus level (i.e. carriage
of both A and B haplotypes) was negatively related to HBsAg carriage. Homozygosity for
group B haplotype was uncommon in this study group (Table 3 and S1 Table). Centromeric
and telomeric KIR genotypes were unrelated to disease status (Fig 2).
Table 2. Effects of KIR genes on immune markers of hepatitis B infection and hepatitis B viral load.
KIR HBsAg-
N (%)
HBsAg+
N (%)
OR 95% CI HBeAg-
N (%)
HBeAg+
N (%)
OR 95% CI Mean Log10HBV virus load
Absent Present P
2DL2 123(84) 88(80) 0.8 0.4–1.4 43(78) 14(88) 2.0 0.4–10.0 4.7 5.7 0.912
2DL3 122(84) 90(82) 0.9 0.5–1.7 45(82) 11(69) 0.5 0.1–1.8 6.7 5.2 0.160
2DL5 92(63) 64(58) 0.8 0.5–1.4 33(60) 11(69) 1.5 0.4–4.9 5.2 5.7 1.000
2DS1 12(8) 12(11) 1.4 0.6–3.2 4(7) 2(13) 1.8 0.3–11.2 5.4 6.9 0.936
2DS2 70(48) 50(46) 0.9 0.6–1.5 24(44) 11(69) 2.8 0.8–9.6 5.4 5.6 1.000
2DS3 68(47) 40(36) 0.7 0.4–1.1 20(36) 8(50) 1.8 0.6–5.5 5.5 5.6 1.000
2DS5 38(26) 36(33) 1.4 0.8–2.4 20(36) 6(38) 1.1 0.3–3.4 5.3 5.9 1.000
3DS1 14(10) 12(11) 1.2 0.5–2.6 2(4) 6(38) 15.9 2.3–112.5 5.3 7.2 0.160
HBsAg: hepatitis B surface antigen, HBeAg: hepatitis B e antigen; N: number of individuals carrying the gene of interest. 110 individuals were HBsAg+, 146
were HBsAg-; 16 individuals were e antigen positive and 55 were e antigen negative; Present: mean LogHBV virus load in those carrying the gene of
interest; Absent: mean LogHBV virus load in those without the gene of interest; OR: Odd ratio; CI: confidence interval; P: p-values corrected for multiple
comparison by the Bonferroni method; Bold: significant association.
https://doi.org/10.1371/journal.pone.0188307.t002
Table 3. KIR genotypes and outcomes of hepatitis B infection.
KIR HBsAg- HBsAg+ OR 95% CI HBeAg- HBeAg+ OR 95% CI Mean Log10HBV virus load
N (%) N (%) N (%) N (%) Absent Present P
Cen genotype
c-AA 6(4) 16(15) 4.0 1.5–10.8 8(15) 1(6) 0.4 0.0–3.5 5.7 4.2 0.147
c-ABx3 2(1) 5(5) 3.4 0.7–18.2 2(4) 0(0) n.a. n.a. 5.6 4.7 1.000
Tel genotype
t-AA 125(86) 89(81) 0.7 0.4–1.4 49(89) 9(56) 0.2 0.0–0.6 6.9 5.2 0.022
t-ABx2 8(6) 6(6) 1.0 0.3–3.0 2(4) 4(25) 8.8 1.3–60.5 5.4 6.6 0.400
Profile
c-AA/t-AA 6(4) 15(14) 3.7 1.4–10.0 8(15) 1(6) 0.4 0.0–3.5 5.7 4.2 0.098
c-AB2/t-AA 24(16) 16(15) 0.9 0.4–1.7 9(16) 2(13) 0.7 0.1–3.8 5.7 4.5 0.156
Haplotype
AA 6(4) 15(14) 3.7 1.4–10.0 8(15) 1(6) 0.4 0.0–3.5 5.7 4.2 0.147
AB 140(96) 92(84) 0.2 0.1–0.6 47(86) 14(88) 1.2 0.2–6.4 4.7 5.7 0.346
BB 0(0) 3(3) n.a. n.a. 0(0) 1(6) n.a. n.a. 5.5. 8.8. n.a.
B content
AB1 92(63) 62(56) 0.8 0.5–1.3 32(58) 6(38) 0.4 0.1–1.4 6.0 5.1 0.318
AB2 44(30) 23(21) 0.6 0.3–1.1 13(24) 6(38) 1.9 0.6–6.5 5.2 6.6 0.045
AB3 4(3) 7(6) 2.4 0.7–8.5) 2(4) 2(13) 3.8 0.5–30.6 5.5 6.5 1.000
HBsAg: hepatitis B surface antigen, HBeAg: hepatitis B e antigen; N: number of individuals carrying the gene of interest; 110 people were HBsAg+, 16 were
e antigen positive. Present: mean LogHBV virus load in those carrying the genotype of interest, Absent: mean LogHBV virus load in those without the
genotype of interest, OR: Odd ratio, CI: confidence interval, P: p-values Bonferroni corrected for multiple testing, n.a.: not applicable. Bold: P<0.05. B
content: 1, 2 and 3 represent the number of B motifs per profile, x: known or novel motifs (e.g. Bx2: second novel B motif identified for the first time in this
study).
https://doi.org/10.1371/journal.pone.0188307.t003
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Discussion
We found that the KIR telomeric AA genotype which is linked to NK cell inhibition was
associated with reduced risk of hepatitis B e antigen carriage. This antigen is a marker of per-
sistent viral replication and accordingly participants with t-AA genotype had significantly
lower viral loads. Conversely carriers homozygous for genes belonging to the group A haplo-
type at both centromeric and telomeric clusters were more likely to be HBsAg-positive. Thus
whilst certain KIR profiles may protect from high levels of viraemia in established infection,
NK cell activation appears to be important in influencing the outcome of infection with the
hepatitis B virus.
Effects of individual KIR genes on hepatitis B infection
Activating KIR genes are relatively infrequent in Africans compared to other populations
worldwide. The low frequency of KIR3DS1 that we observed agrees with published KIR gene
frequency data from Sub-Saharan Africa [44,45,46]. We found that carriers of KIR3DS1were
more likely to be HBeAg positive and to have high viral loads, although our estimates of the
size of the effect are imprecise because of the low gene frequency and small sample sizes.
Whilst participants with the inhibitory KIR2DL3 gene had lower virus loads these differ-
ences were not significant in our study. Previous reports have suggested an association
between KIR2DL3 and clearance of hepatitis C virus with subsequent protection from chronic
hepatitis, and liver damage [47,48]. These associations are strongest when KIR2DL3 is present
together with its ligand HLA-C group 1. Recent studies showed that HLA-C1 homozygosity
either individually or in combination with KIR2DL3 is associated with outcomes of HBV infec-
tion such as chronic HBV carriage and HCC [36,47]. Further studies are needed either to
establish an independent effect of KIR2DL3 in hepatitis B infection or to confirm the protective
effect of KIR2DL3/HLA-C combinations.
Fig 2. Centromeric and telomeric genotype distribution. a) Genomic organisation of centromeric genotypes
present in at least 2% of the study population, b) KIR genes present telomeric genotypes (those found in at least 2%
of the study population). Filled box: gene is present; open box: gene is absent, x: known or novel motifs (e.g. Bx2:
second novel B motif identified for the first time in this study), N: number of individuals carrying the genotype of
interest.
https://doi.org/10.1371/journal.pone.0188307.g002
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Centromeric and telomeric haplotypes and KIR profiles
More than 80% of centromeric and telomeric genotypes and KIR profiles in this study were
previously unreported and are likely to be specific to West Africa. The genotype c-AA is the
most common centromeric genotype observed worldwide [31,33] although we found it to be
less frequent in Gambians. The only activating gene on this genotype is KIR2DS4which is
sometimes not expressed [49,50].
At the telomeric cluster t-AA genotypes predominate, as has been observed in studies on
previous Gambian and other West African populations [51]. We discovered previously unde-
scribed B motifs one of which (t-Bx2) differs from the common telomeric A motif (t-A) only
by the presence of KIR3DS1. Carriers of both of these motifs (t-ABx2 genotype) were more
likely to be HBeAg-positive with higher HBV viral loads than those negative for this genotype.
In all, 45 different KIR profiles were found in 279 participants, the most common of which
resulted from a recombination of genes belonging to group A and B haplotypes. Homozygosity
for group A KIR content-haplotype was observed in less than 10% of Gambians which is
unusual when compared to other population groups worldwide [42].
Potential pathological mechanisms
It is interesting that the activating KIR3DS1 is associated with e antigen positivity and high
viral loads. In addition, haplotypes carrying other activating KIR genes were generally linked
to clearance of the surface antigen. It may be that cytolysis and inflammatory mediators gener-
ated by NK cells are important in controlling the initial infection but if unsuccessful then per-
sistent inflammation with consequent inflammatory cell recruitment promotes conditions
favourable to viral replication. The finding that activating KIR is linked to higher viral loads is
in keeping with other studies which have linked activating KIR to virus related cancers [20,21]
and to persistent viraemia in HCV [22], although telomeric B haplotypes are associated with
slow progression of chronic hepatitis C infection in American Aboriginals [32,33].
Implications for future research
HBV is the commonest cause of liver cancer deaths and cirrhosis deaths globally with most
deaths occurring in low-income countries [1]. This is the first study to examine associations
between common immune markers and liver disease in a low-income country with high hepa-
titis B prevalence. Future studies on a larger scale might explore these associations further pro-
viding useful mechanistic insights into pathogenesis of chronic liver disease and cancer in this
context.
Whilst this investigation is the first to provide evidence that centromeric and telomeric KIR
genotypes may be important in governing host immune responses to hepatitis B infection in
Gambians, we had insufficient participants and limited genomic material to investigate the
effects of HLA alleles. Participation therefore was restricted only to those for whom an ade-
quate amount of DNA was available for KIR typing.
Additionally, in this small investigation we were unable to demonstrate the effect of func-
tional KIR genes on longer term outcomes of infection such as cirrhosis and cancer. Larger
studies will be necessary to provide sufficient power to examine these outcomes and may also
provide the opportunity to look for effects on response to treatment for hepatitis B infection.
Given the relatively large effect sizes that we observed and the lack of correlation between risk
factors, hepatitis outcomes and KIR gene frequencies with reported ethnicity it seems unlikely
that undetected population stratification would account for our findings. However this may be
more of a problem in larger scale studies over wider geographical areas and it would thus be
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prudent to use a genomic control or structured association method to adjust for this in the
analysis.
It is possible that KIR or HLA alleles and HLA/KIR compound genotypes will exert selective
pressure on the hepatitis B virus over time in populations. In our study, viral sequences were
not available to examine this hypothesis. However, such selection pressure might have impor-
tant clinical effects, for example the emergence of strains carrying mutations that affect trans-
mission or alter the configuration of proteins which are the targets of antiviral drugs. These
important questions should be examined in future work which might be more effectively car-
ried out in populations with higher frequencies of activating KIR genes and increased rates of
homozygosity.
Conclusions
This study evaluated the role of centromeric and telomeric KIR genes on outcomes of viral
hepatitis infection in adult Gambians with liver disease (hepatocellular carcinoma or cirrhosis)
and matched controls. We show for the first time that homozygosity for KIR genes belonging
to the group A haplotype at the telomeric part of the KIR locus is associated with reduced risk
of e antigenaemia and lower viral loads. Heterozygosity for A and B haplotypes was associated
with clearance of HBsAg and control of the initial HBV infection. The mechanisms through
which KIR genes mediate these effects warrant further assessment in larger studies.
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